ORF6, a repressor of the MHC class I pathway: new molecular target for SARS-CoV-2 drug discovery?

Expert Opin Ther Targets. 2023 Jul-Dec;27(8):639-644. doi: 10.1080/14728222.2023.2248377. Epub 2023 Aug 30.

Baohui Zhu¹, Ryota Ouda¹, Paul de Figueiredo², Koichi S Kobayashi^{1

3

4}

¹ Department of Immunology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
² Christopher S. Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, and Department of Veterinary Pathobiology, University of Missouri, Columbia, MO, USA.
³ Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Sapporo, Japan.
⁴ Department of Microbial Pathogenesis and Immunology, Texas A&M Health Science Center, Bryan, TX, USA.

No abstract available

Keywords: COVID-19; MHC class I; NLRC5; SARS-CoV-2; immune evasion.

Publication types